Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Study to Ablate Oligometastatic Prostate Cancer by Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy and to Characterize Its Molecular Phenotype

NCT04031378 is registered in ClinicalTrials.gov with Fundacao Champalimaud as lead sponsor.

NCT NCT04031378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04031378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Study to Ablate Oligometastatic Prostate Cancer by Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy and to Characterize Its Molecular Phenotype
Lead sponsor
Fundacao Champalimaud
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2019
Completion date
November 1, 2022
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer, prostate adenocarcinoma